RECRUITING

Losartan in Prevention of Radiation-Induced Heart Failure

Description

This study is being done to see if losartan affects the chances of developing radiation-induced heart failure in patients who are receiving radiation therapy as part of standard of care treatment for breast cancer. The interventions involved in this study are: * Losartan * Radiation Therapy (standard of care)

Study Overview

Study Details

Study overview

This study is being done to see if losartan affects the chances of developing radiation-induced heart failure in patients who are receiving radiation therapy as part of standard of care treatment for breast cancer. The interventions involved in this study are: * Losartan * Radiation Therapy (standard of care)

The Role of Losartan in the Prevention of Early Structural Changes Associated With Radiation-Induced Heart Failure

Losartan in Prevention of Radiation-Induced Heart Failure

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States, 02114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Non-metastatic Breast Cancer patients who are scheduled to receive conventional left breast/chest wall RT inclusive of treatment to the internal mammary lymph nodes (IMNs)
  • * Prior chemotherapy is permitted
  • * Patients must have Left-sided Breast Cancer
  • * Ability to understand and the willingness to sign a written informed consent document
  • * No contraindication to MRI
  • * Person who is pregnant or breastfeeding.
  • * Patient unable to swallow oral medication.
  • * Patients receiving any other investigational agent will not be excluded from study eligibility, unless the patient is already enrolled in an interventional study evaluating cardiac toxicity
  • * Patients already receiving ACE/ARBs.
  • * Patients with a history of allergic reactions to Losartan biosimilars.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts General Hospital,

Rachel Jimenez, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

2024-12-01